A Case of Adjuvant Treatment with Sorafenib after Radiotherapy for Brain Metastasis from Poorly Differentiated Thyroid Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Sorafenib is an emerging therapeutic option for radioactive iodine (RAI)-refractory differentiated thyroid carcinoma. However, the effects of sorafenib as an adjuvant treatment following surgery or radiation on brain metastases from poorly differentiated thyroid carcinoma (PDTC) have never been reported. A 52-year-old patient underwent total thyroidectomy for follicular thyroid carcinoma. Despite high-dose RAI therapy, a neck mass and lung metastases were developed. PDTC was diagnosed by neck mass removal. During adjuvant external beam radiation therapy (EBRT) to the neck, brain metastases developed. After palliative EBRT for brain metastases, the brain tumor size decreased but lung metastases markedly progressed. Off-label sorafenib was used to treat progressive multiple metastatic lesions. Over five months of sorafenib treatment, the sum of the longest diameters for target lesions was decreased by 45% in brain and 13% in lung. Sorafenib can be considered a new adjuvant therapeutic option for metastatic brain lesions from PDTC after EBRT.
Abstract
Sorafenib is an emerging therapeutic option for radioactive iodine (RAI)-refractory differentiated thyroid carcinoma. However, the effects of sorafenib as an adjuvant treatment following surgery or radiation on brain metastases from poorly differentiated thyroid carcinoma (PDTC) have never been reported. A 52-year-old patient underwent total thyroidectomy for follicular thyroid carcinoma. Despite high-dose RAI therapy, a neck mass and lung metastases were developed. PDTC was diagnosed by neck mass removal. During adjuvant external beam radiation therapy (EBRT) to the neck, brain metastases developed. After palliative EBRT for brain metastases, the brain tumor size decreased but lung metastases markedly progressed. Off-label sorafenib was used to treat progressive multiple metastatic lesions. Over five months of sorafenib treatment, the sum of the longest diameters for target lesions was decreased by 45% in brain and 13% in lung. Sorafenib can be considered a new adjuvant therapeutic option for metastatic brain lesions from PDTC after EBRT.
참고문헌 (20)
- Ikekubo K, "Seven cases of brain metastasis from papillary thyroid carcinoma", Kaku Igaku, 37(4), pp.349~357 (2000)
- Henriques de Figueiredo B, "Brain metastases from thyroid carcinoma: a retrospective study of 21 patients", Thyroid, 24(2), pp.270~276 (2014)
- Sanders EM Jr, "An evidence-based review of poorly differentiated thyroid cancer", World J Surg, 31(5), pp.934~945 (2007)
- Hannallah J, "Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma", Int J Endocrinol, 2013, pp.317487~ (2013)
- Lyons JF, "Discovery of a novel Raf kinase inhibitor", Endocr Relat Cancer, 8(3), pp.219~225 (2001)
- Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90(12), pp.6373~6379 (2005)
- Fenton C, "The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults", Thyroid, 10(4), pp.349~357 (2000)
- Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
- Kakudo K, "Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute", Pathol Int, 59(6), pp.359~367 (2009)
- Patel KN, "Poorly differentiated thyroid cancer", Curr Opin Otolaryngol Head Neck Surg, 22(2), pp.121~126 (2014)
- McWilliams RR, "Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25years", Cancer, 98(2), pp.356~362 (2003)
- Bernad DM, "Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers", J Neurooncol, 98(2), pp.249~252 (2010)
- Chen L, "Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma", Thyroid, 21(2), pp.119~124 (2011)
- Shen Y, "Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib", Thyroid, 22(8), pp.856~860 (2012)
- Krajewska J, "Treatment with sorafenib in advanced thyroid cancer - a case report", Endokrynol Pol, 61(5), pp.492~496 (2010)
- Lagas JS, "Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation", Mol Cancer Ther, 9(2), pp.319~326 (2010)
- Marra A, "Late cerebral radionecrosis", Eur Neurol, 1(4), pp.234~246 (1968)
- Girard N, "Sorafenib and radiotherapy association for hepatocellular carcinoma", Cancer Radiother, 15(1), pp.77~80 (2011)
- Cabanillas ME, "Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience", J Clin Endocrinol Metab, 95(6), pp.2588~2595 (2010)
- Cabanillas ME, "Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer", J Thyroid Res, 2011, pp.985780~ (2011)